Aptinyx Advances NMDA Receptor Modulators To Ease Pain
In the two years since Aptinyx was spun-out from predecessor Naurex, the US biotech has gone from being a preclinical company to one with two Phase II programs and a third to enter that stage in 3Q 2018. Company president and CEO, Norbert Riedel met up with Scrip at the 2018 Biotech Showcase and revealed how Aptinyx intends to spend the $70m it raised in a series B financing late last year.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.